JACKSONVILLE, Fla., Nov. 22, 2005 (PRIMEZONE) -- Phlo Corporation (Pink Sheets:PHLC) ("Phlo") announced today that the AQUIS(tm) Rapid Response Rehydration product line of one of its affiliates will be distributed by Medco Supply Company ("Medco"), one of the world's largest suppliers of medical products to athletic trainers, sports medicine professionals, physical therapists and schools. Medco will offer AQUIS(tm) for sale online within approximately 30 days and will feature AQUIS(tm) in its sports medicine catalog to be released in March 2006. Medco is a division of Patterson Companies, the world's leading distributor of rehabilitation supplies and other medical products.
AQUIS(tm) Rapid Response Rehydration solutions are based on the Company's patent-pending MEDS (Micro-Encapsulation Delivery System) technology which allows for immediate absorption of the electrolyte payload into the bloodstream, beginning through the mucous membranes of the mouth. This micro-encapsulation of the electrolytes allows AQUIS(tm) to taste good (no salty taste), encouraging consumption prior to the point of dehydration.
The Company plans to continue to announce further developments on the sales front.
Phlo also announced today that on November 15, 2005, it filed with the Securities and Exchange Commission its Form 10-KSB for the fiscal year ended March 31, 2005. Phlo will be current in its periodic filings upon the filing of its Forms 10-QSB for the fiscal quarters ended June 30, 2005 and September 30, 2005, and believes that it will accomplish that goal in the very near future. However, Phlo cannot make any assurances with respect to the exact dates upon which such filings will be made due to factors normally associated with such a process which are not under the control of Phlo.
Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patents-pending biotechnologies which are sold on a commercial basis to governmental and institutional purchasers and to high volume chain stores, such as supermarkets and drug and convenience stores. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.
Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.